Strides Arcolab announces USFDA approval for Buspirone Tablets

Image
Capital Market
Last Updated : Aug 26 2014 | 5:02 PM IST

On 26 August 2014

Strides Arcolab announced that the Company has received US FDA approval for Buspirone Hydrochloride Tablets USP, 5 mg, 10 mg, 15 mg and 30 mg. The product will be manufactured at the Company's oral dosage facility in Bangalore and marketed directly by Strides in the US market.

The Buspirone Tablets are used for the treatment of anxiety disorders and the short term relief of the symptoms of anxiety.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 26 2014 | 4:03 PM IST

Next Story